DorsaVi (ASX: DVL)
Technology
A Hidden ASX AI Play at the Intersection of Robotics and Semiconductors Technology
We initiate coverage on DorsaVi Limited (ASX: DVL) with a 12-month target price of A$0.16, implying a material upside of ~440% from current levels. A differentiated positioning at the convergence of wearable sensing, proprietary data and ultra-edge AI underpins this. The investment case rests on a dual-engine growth strategy that combines an established, revenue-generating clinical platform with an emerging intelligence business.
The company is moving decisively up the value chain from sensing hardware to on-device intelligence. This transition leverages its installed base and proprietary datasets to deliver lower latency, reduced reliance on the cloud, and higher-value products with stronger differentiation, pricing power, and scalable recurring revenues.
RRAM and neuromorphic foundation accelerating edge intelligence expansion
DorsaVi has secured proprietary RRAM and neuromorphic processing capabilities, establishing a strong foundation in next-generation, low-power computing architectures. These technologies address critical constraints in data movement and energy efficiency, enabling real-time intelligence directly at the point of decision and shifting value to higher-margin applications. The transition to the 22nm RRAM represents a key step towards commercial readiness, improving performance, density and scalability within standard manufacturing processes. With limited competition from the existing embedded chips, 22nm RRAM platform underpins DVL’s expansion into intelligent robotics, where tightly integrated sensing and on-device intelligence enable adaptive human–machine interaction, positioning the Company for structurally higher value growth.
Recurring revenue base, strengthening platform scale and validation
The sensor business provides a stable, growing base of recurring revenue, anchoring the commercial model and improving earnings visibility. The rollout of the v6.5 platform, with enhanced analytics, usability, and data-capture capabilities, is driving stronger adoption and engagement. As the installed base expands, it increases repeat usage, deepens customer relationships and supports a more predictable and scalable revenue profile.
Exposure to large and expanding end markets
DVL is targeting multiple high-growth markets, including sports performance, workplace safety, robotics and edge AI, where demand for real-time, low-power intelligence is accelerating. Its cross-deployable platform enables expansion into larger addressable markets, supporting scalable revenue growth and long-term operating leverage.
Valuation range of A$0.13–0.18 per share
Using a DCF-based methodology, we have valued DVL at a midpoint target price of A$0.16, representing a Price/NAV of 0.19x and indicating significant upside (~440%) relative to the current share price. As RRAM platform matures, it will support higher-level capabilities, positioning DVL to move beyond potential IP licensing or co-development models, creating high-margin revenue stream. Simultaneously, the clinical sensor business will provide a recurring revenue base that supports cash flow stability and enhances earnings visibility. The next 18-24 months will be a critical period for executing RRAM design, scaling clinical network expansion, and deepening strategic partnerships. DVL is transitioning towards a niche MedTech platform with emerging exposure to semiconductor design and improving revenue visibility. Key risks include slower network expansion, delays in RRAM revenue generation, and execution risks for new commercial initiatives.